Quantcast
Last updated on April 17, 2014 at 10:25 EDT

Latest osteosarcoma Stories

2011-09-15 14:32:00

NEW YORK, Sept. 15, 2011 /PRNewswire-USNewswire/ -- Many published human and animal studies have reported an association between fluoride and various cancers, including valid and unrefuted scientific evidence that fluoride can increase the risk of osteosarcoma (a type of bone cancer) in boys and young men, reports the Fluoride Action Network (FAN) in its recent submission to the California Environmental Protection Agency's Office of Environmental Health Hazard Assessment (OEHHA). (1)...

2011-08-02 14:26:00

NEW YORK, Aug. 2, 2011 /PRNewswire-USNewswire/ -- A paper in the Journal of Dental Research by dentist Chester Douglass and colleagues, "An Assessment of Bone Fluoride and Osteosarcoma," (7/28/11) claims to show no association between fluoride bone levels and osteosarcoma, a form of bone cancer. However, Douglass' study has serious scientific flaws and is incapable of disproving a previous study (Bassin et al., 2006) which linked water fluoridation to osteosarcoma, reports the Fluoride...

381c43c5ac0139c3e8d2aee5a697bced
2011-07-29 09:00:34

A new University of Minnesota discovery may help bone cancer patients fight their disease more effectively, according to new research published in the September issue of Bone. Bone cancer typically affects children; the course and aggressiveness of the disease can vary from patient to patient and is very difficult to predict. Some patients respond remarkably well to conventional therapies. Their disease shows less aggressive behavior and they can survive for decades without recurrence. Others...

2011-07-28 18:14:00

The International and American Associations for Dental Research have released in its Journal of Dental Research a study that investigated bone fluoride levels in individuals with osteosarcoma, which is a rare, primary malignant bone tumor that is more prevalent in males. Since there has been controversy as to whether there is an association between fluoride and risk for osteosarcoma, the purpose of this study, titled "An Assessment of Bone Fluoride and Osteosarcoma," was to determine if bone...

2011-07-28 12:00:00

CHICAGO, July 28, 2011 /PRNewswire-USNewswire/ -- A new study in the Journal of Dental Research finds bone fluoride levels are not associated with osteosarcoma, a rare bone cancer more prevalent in males. A team of researchers from Harvard University, the Medical College of Georgia and the National Cancer Institute analyzed hundreds of bone samples from nine hospitals over an eight-year period from patients with osteosarcoma and a control group to measure fluoride levels in the bone....

2011-06-09 10:30:00

WEST CHESTER, Pa. and INDIANAPOLIS, June 9, 2011 /PRNewswire/ -- Synthes, Inc. (SIX: SYST.VX) and Eli Lilly and Company (NYSE: LLY) today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures. The agreement allows for the joint development and licensing of early stage compounds from Lilly to Synthes for use within orthopedic trauma,...

2011-06-08 14:07:24

Dual approach will find mutations in osteosarcoma and develop tools to monitor disease in patients A new study into osteosarcoma - cancer of the bone - will use advances in genomic research and analysis to identify new genes that give rise to the condition and to create personalised blood tests for children and young adults with the condition. The study is funded by Skeletal Action Cancer Trust, SCAT. It is hoped that the results of this new study will help doctors improve treatment of this...

2011-05-27 16:00:00

INDIANAPOLIS, May 27, 2011 /PRNewswire/ -- In the press release, "Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas," issued May 19, 2011, by Eli Lilly and Company (NYSE: LLY), the following sentence has been amended to: The best overall responses were as follows: one partial response in the Ewing sarcoma tier (n=1); and no partial responses, but stable disease of 41 percent (n=9) in leiomyosarcoma; 35 percent (n=6) in synovial sarcoma; 28 percent (n=5) in Ewing family of...

2011-05-19 07:10:00

INDIANAPOLIS, May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body. Study results demonstrated that 57 percent of patients with a soft tissue sarcoma known as adipocytic sarcoma (a rare tumor that develops from fat cells) experienced stable disease. Results from the Phase II study will be presented on Monday, June 6 at 4:15 p.m. CDT...

2011-03-17 15:15:00

INDIANAPOLIS, March 17, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients should not use the alcohol prep pads made by the Triad Group that are contained in the black starter kits for Forteo® [teriparatide (rDNA origin) injection] in the United States. The Triad Group is recalling the alcohol prep pads due to potential contamination with the bacteria, Bacillus cereus, which could result in life threatening infections, especially in...